RNAi therapy to the wall of arteries and veins: Anatomical, physiologic, and pharmacological considerations

Journal of Translational Medicine

Volumn 15, Issue 1, 2017, Pages

  Nabzdyk, Christoph S ^a,b   Pradhan Nabzdyk, Leena ^b   LoGerfo, Frank W ^b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADAMTS7 PROTEIN; BETA3 INTEGRIN; CD31 ANTIGEN; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; GELATINASE B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; KRUPPEL LIKE FACTOR 2; MICRORNA; MICRORNA 101; MICRORNA 10A; MICRORNA 126; MICRORNA 126 3P; MICRORNA 143; MICRORNA 145; MICRORNA 145 5P; MICRORNA 155; MICRORNA 23; MICRORNA 24; MICRORNA 27; MICRORNA 663; MICRORNA 92A; MONOCYTE CHEMOTACTIC PROTEIN 1; PROCOLLAGEN C PROTEINASE; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR GATA 2; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULAR CELL ADHESION MOLECULE 1; VASCULOTROPIN A;

AORTIC ANEURYSM; ARTERY INTIMA PROLIFERATION; ARTERY WALL; ATHEROSCLEROSIS; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR PARAMETERS; CELL DIFFERENTIATION; CELLULAR DISTRIBUTION; ENDOTHELIUM CELL; GENE DELIVERY SYSTEM; GENE EXPRESSION; GENE TARGETING; GENE THERAPY; GENETIC TRANSFECTION; HUMAN; MORBIDITY; NONHUMAN; REVIEW; RNA INTERFERENCE; VASCULAR SMOOTH MUSCLE CELL; VEIN WALL; ANATOMY AND HISTOLOGY; ANIMAL; ARTERY; METABOLISM; PHYSIOLOGY; RNAI THERAPEUTICS; TRANSLATIONAL RESEARCH; VEIN;

ANIMALS; ARTERIES; HUMANS; MICRORNAS; RNA, SMALL INTERFERING; RNAI THERAPEUTICS; TRANSLATIONAL MEDICAL RESEARCH; VEINS;

EID: 85026380237     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/s12967-017-1270-0     Document Type: Review

References (116)

1. Lam JK, et al. siRNA versus miRNA as therapeutics for gene silencing. Mol Ther Nucleic Acids. 2015;4:e252.
2. Doench JG, Petersen CP, Sharp PA. siRNAs can function as miRNAs. Genes Dev. 2003;17(4):438-42.
3. Gareri C, De Rosa S, Indolfi C. MicroRNAs for restenosis and thrombosis after vascular injury. Circ Res. 2016;118(7):1170-84.
4. Urbich C, Kuehbacher A, Dimmeler S. Role of microRNAs in vascular diseases, inflammation, and angiogenesis. Cardiovasc Res. 2008;79(4):581-8.
5. Latronico MV, Catalucci D, Condorelli G. Emerging role of microRNAs in cardiovascular biology. Circ Res. 2007;101(12):1225-36.
6. Hwang HW, Wentzel EA, Mendell JT. A hexanucleotide element directs microRNA nuclear import. Science. 2007;315(5808):97-100.
7. Pradhan-Nabzdyk L, et al. Current siRNA targets in the prevention and treatment of intimal hyperplasia. Discov Med. 2014;18(98):125-32.
8. Pradhan-Nabzdyk L, et al. Current siRNA targets in atherosclerosis and aortic aneurysm. Discov Med. 2014;17(95):233-46.
9. Nabzdyk CS, et al. High throughput RNAi assay optimization using adherent cell cytometry. J Transl Med. 2011;9:48.
10. Nabzdyk CS, et al. Differential susceptibility of human primary aortic and coronary artery vascular cells to RNA interference. Biochem Biophys Res Commun. 2012;425(2):261-5.
11. Andersen ND, et al. Endothelial cells are susceptible to rapid siRNA transfection and gene silencing ex vivo. J Vasc Surg. 2010;52(6):1608-15.
12. Andersen ND, et al. Comparison of gene silencing in human vascular cells using small interfering RNAs. J Am Coll Surg. 2007;204(3):399-408.
13. Nabzdyk CS, et al. RNA interference-mediated survivin gene knockdown induces growth arrest and reduced migration of vascular smooth muscle cells. Am J Physiol Heart Circ Physiol. 2011;301(5):H1841-9.
14. You B, et al. Activation of sphingosine kinase-1 mediates inhibition of vascular smooth muscle cell apoptosis by hyperglycemia. Diabetes. 2007;56(5):1445-53.
15. Hu XH, et al. Effect of RNA interference targeting mammalian target of rapamycin on the proliferation of vascular smooth muscle cell and the intimal hyperplasia. Zhonghua Yi Xue Za Zhi. 2007;87(1):58-62.
16. Winter PM, et al. Endothelial alpha(v)beta3 integrin-targeted fumagillin nanoparticles inhibit angiogenesis in atherosclerosis. Arterioscler Thromb Vasc Biol. 2006;26(9):2103-9.
17. Wolinsky H, Glagov S. Comparison of abdominal and thoracic aortic medial structure in mammals. Deviation of man from the usual pattern. Circ Res. 1969;25(6):677-86.
18. Jones Buie JN, et al. The role of miRNAs in cardiovascular disease risk factors. Atherosclerosis. 2016;254:271-81.
19. Hall JL, et al. Hyperglycemia inhibits vascular smooth muscle cell apoptosis through a protein kinase C-dependent pathway. Circ Res. 2000;87(7):574-80.
20. Welten SM, et al. The multifactorial nature of microRNAs in vascular remodelling. Cardiovasc Res. 2016;110(1):6-22.
21. Leistner DM, et al. Transcoronary gradients of vascular miRNAs and coronary atherosclerotic plaque characteristics. Eur Heart J. 2016;37(22):1738-49.
22. Eken SM, et al. MicroRNA-210 enhances fibrous cap stability in advanced atherosclerotic lesions. Circ Res. 2016.
23. Loyer X, et al. MicroRNAs as therapeutic targets in atherosclerosis. Expert Opin Ther Targets. 2015;19(4):489-96.
24. Cao H, et al. Upregulation of let-7a inhibits vascular smooth muscle cell proliferation in vitro and in vein graft intimal hyperplasia in rats. J Surg Res. 2014;192(1):223-33.
25. Maier KG, et al. Thrombospondin-1 differentially regulates microRNAs in vascular smooth muscle cells. Mol Cell Biochem. 2016;412(1-2):111-7.
26. Conte MS, et al. Results of PREVENT III: a multicenter, randomized trial of edifoligide for the prevention of vein graft failure in lower extremity bypass surgery. J Vasc Surg. 2006;43(4):742-51 (discussion 751).
27. Conte MS, et al. Design and rationale of the PREVENT III clinical trial: edifoligide for the prevention of infrainguinal vein graft failure. Vasc Endovasc Surg. 2005;39(1):15-23.
28. Bools LM, et al. Comparative analysis of polymers for short interfering RNA delivery in vascular smooth muscle cells. J Surg Res. 2015;199(1):266-73.
29. Raof NA, et al. The effects of transfection reagent polyethyleneimine (PEI) and non-targeting control siRNAs on global gene expression in human aortic smooth muscle cells. BMC Genom. 2016;17:20.
30. Isayama N, Matsumura G, Yamazaki K. Comparison of vascular smooth muscle cells in canine great vessels. BMC Vet Res. 2013;9:54.
31. Lillvis JH, et al. Regional expression of HOXA4 along the aorta and its potential role in human abdominal aortic aneurysms. BMC Physiol. 2011;11:9.
32. Drusco A, et al. Knockout mice reveal a tumor suppressor function for Testin. Proc Natl Acad Sci USA. 2005;102(31):10947-51.
33. Archacki SR, et al. Comparative gene expression analysis between coronary arteries and internal mammary arteries identifies a role for the TES gene in endothelial cell functions relevant to coronary artery disease. Hum Mol Genet. 2012;21(6):1364-73.
34. Deng DX, et al. Molecular signatures determining coronary artery and saphenous vein smooth muscle cell phenotypes: distinct responses to stimuli. Arterioscler Thromb Vasc Biol. 2006;26(5):1058-65.
35. Turner NA, et al. Smooth muscle cells cultured from human saphenous vein exhibit increased proliferation, invasion, and mitogen-activated protein kinase activation in vitro compared with paired internal mammary artery cells. J Vasc Surg. 2007;45(5):1022-8.
36. Faries PL, et al. Vascular smooth muscle cells derived from atherosclerotic human arteries exhibit greater adhesion, migration, and proliferation than venous cells. J Surg Res. 2002;104(1):22-8.
37. Chanakira A, et al. Hypoxia differentially regulates arterial and venous smooth muscle cell proliferation via PDGFR-beta and VEGFR-2 expression. Am J Physiol Heart Circ Physiol. 2012;302(5):H1173-84.
38. Cordes KR, et al. miR-145 and miR-143 regulate smooth muscle cell fate and plasticity. Nature. 2009;460(7256):705-10.
39. Albinsson S, Sward K. Targeting smooth muscle microRNAs for therapeutic benefit in vascular disease. Pharmacol Res. 2013;75:28-36.
40. Climent M, et al. TGFbeta triggers miR-143/145 transfer from smooth muscle cells to endothelial cells, thereby modulating vessel stabilization. Circ Res. 2015;116(11):1753-64.
41. Aird WC. Endothelial cell heterogeneity. Crit Care Med. 2003;31(4 Suppl):S221-30.
42. Weinberg EJ, et al. Hemodynamic environments from opposing sides of human aortic valve leaflets evoke distinct endothelial phenotypes in vitro. Cardiovasc Eng. 2010;10(1):5-11.
43. Beets K, et al. BMP-SMAD signalling output is highly regionalized in cardiovascular and lymphatic endothelial networks. BMC Dev Biol. 2016;16(1):34.
44. de Vinuesa GA. BMP signaling in vascular biology and dysfunction. Cytokine Growth Factor Rev. 2016;27:65-79.
45. Kumar S, et al. Role of flow-sensitive microRNAs in endothelial dysfunction and atherosclerosis: mechanosensitive athero-miRs. Arterioscler Thromb Vasc Biol. 2014;34(10):2206-16.
46. van de Water FM, et al. Intravenously administered short interfering RNA accumulates in the kidney and selectively suppresses gene function in renal proximal tubules. Drug Metab Dispos. 2006;34(8):1393-7.
47. Wahlestedt C, et al. Potent and nontoxic antisense oligonucleotides containing locked nucleic acids. Proc Natl Acad Sci USA. 2000;97(10):5633-8.
48. Mook OR, et al. Evaluation of locked nucleic acid-modified small interfering RNA in vitro and in vivo. Mol Cancer Ther. 2007;6(3):833-43.
49. Lv H, et al. Toxicity of cationic lipids and cationic polymers in gene delivery. J Control Release. 2006;114(1):100-9.
50. Whitehead KA, Langer R, Anderson DG. Knocking down barriers: advances in siRNA delivery. Nat Rev Drug Discov. 2009;8(2):129-38.
51. Ishida T, Harashima H, Kiwada H. Liposome clearance. Biosci Rep. 2002;22(2):197-224.
52. Semple SC, et al. Immunogenicity and rapid blood clearance of liposomes containing polyethylene glycol-lipid conjugates and nucleic acid. J Pharmacol Exp Ther. 2005;312(3):1020-6.
53. Bozzuto G, Molinari A. Liposomes as nanomedical devices. Int J Nanomed. 2015;10:975-99.
54. Gref R, et al. Poly(ethylene glycol)-coated nanospheres: potential carriers for intravenous drug administration. Pharm Biotechnol. 1997;10:167-98.
55. Gref R, et al. The controlled intravenous delivery of drugs using PEG-coated sterically stabilized nanospheres. Adv Drug Deliv Rev. 1995;16(2-3):215-33.
56. Harris JM, Martin NE, Modi M. Pegylation: a novel process for modifying pharmacokinetics. Clin Pharmacokinet. 2001;40(7):539-51.
57. Heyes J, et al. Synthesis and characterization of novel poly(ethylene glycol)-lipid conjugates suitable for use in drug delivery. J Control Release. 2006;112(2):280-90.
58. Nabzdyk CS, et al. Gene silencing in human aortic smooth muscle cells induced by PEI-siRNA complexes released from dip-coated electrospun poly(ethylene terephthalate) grafts. Biomaterials. 2014;35(9):3071-9.
59. Bodewes TC, et al. Intraluminal delivery of thrombospondin-2 small interfering RNA inhibits the vascular response to injury in a rat carotid balloon angioplasty model. FASEB J. 2016.
60. Lee D, et al. Bioreducible crosslinked polyelectrolyte complexes for MMP-2 siRNA delivery into human vascular smooth muscle cells. Pharm Res. 2012;29(8):2213-24.
61. Nicoli E, et al. Enhanced gene silencing through human serum albumin-mediated delivery of polyethylenimine-siRNA polyplexes. PLoS ONE. 2015;10(4):e0122581.
62. Shi J, et al. Hybrid lipid-polymer nanoparticles for sustained siRNA delivery and gene silencing. Nanomedicine. 2014;10(5):897-900.
63. McLendon JM, et al. Lipid nanoparticle delivery of a microRNA-145 inhibitor improves experimental pulmonary hypertension. J Control Release. 2015;210:67-75.
64. Tripathy S, et al. High density lipoprotein nanoparticles deliver RNAi to endothelial cells to inhibit angiogenesis. Part Part Syst Charact. 2014;31(11):1141-50.
65. Haussecker D. Current issues of RNAi therapeutics delivery and development. J Control Release. 2014;195:49-54.
66. Lu P, et al. Effect of GPE-AGT nanoparticle shRNA transfection system mediated RNAi on early atherosclerotic lesion. Int J Clin Exp Pathol. 2012;5(7):698-706.
67. Kulkarni RK, et al. Biodegradable poly(lactic acid) polymers. J Biomed Mater Res. 1971;5(3):169-81.
68. Mukerjee A, et al. Efficient nanoparticle mediated sustained RNA interference in human primary endothelial cells. Nanotechnology. 2011;22(44):445101.
69. Liu X, et al. Inhibition of hypoxia-induced proliferation of pulmonary arterial smooth muscle cells by a mTOR siRNA-loaded cyclodextrin nanovector. Biomaterials. 2014;35(14):4401-16.
70. Yang J, et al. Lentivirus-mediated RNAi targeting CREB binding protein attenuates neointimal formation and promotes re-endothelialization in balloon injured rat carotid artery. Cell Physiol Biochem. 2010;26(3):441-8.
71. Chen G, et al. Construction of NF-kappaB-targeting RNAi adenovirus vector and the effect of NF-kappaB pathway on proliferation and apoptosis of vascular endothelial cells. Mol Biol Rep. 2011;38(5):3089-94.
72. Kasahara H, Aoki H. Gene silencing using adenoviral RNAi vector in vascular smooth muscle cells and cardiomyocytes. Methods Mol Med. 2005;112:155-72.
73. Yang J, et al. MicroRNA-24 attenuates neointimal hyperplasia in the diabetic rat carotid artery injury model by inhibiting Wnt4 signaling pathway. Int J Mol Sci. 2016;17(6):765.
74. Yang J, et al. MicroRNA-24 inhibits high glucose-induced vascular smooth muscle cell proliferation and migration by targeting HMGB1. Gene. 2016;586(2):268-73.
75. Lai YK, et al. Potential long-term inhibition of ocular neovascularisation by recombinant adeno-associated virus-mediated secretion gene therapy. Gene Ther. 2002;9(12):804-13.
76. Maguire AM, et al. Safety and efficacy of gene transfer for Leber's congenital amaurosis. N Engl J Med. 2008;358(21):2240-8.
77. Bainbridge JW, et al. Effect of gene therapy on visual function in Leber's congenital amaurosis. N Engl J Med. 2008;358(21):2231-9.
78. Weinberg MS, et al. Recombinant adeno-associated virus utilizes cell-specific infectious entry mechanisms. J Virol. 2014;88(21):12472-84.
79. Zhang Y, Wang Z, Gemeinhart RA. Progress in microRNA delivery. J Control Release. 2013;172(3):962-74.
80. Pahle J, Walther W. Vectors and strategies for nonviral cancer gene therapy. Expert Opin Biol Ther. 2016;16(4):443-61.
81. Malabanan KP, et al. Activation transcription factor-4 induced by fibroblast growth factor-2 regulates vascular endothelial growth factor-A transcription in vascular smooth muscle cells and mediates intimal thickening in rat arteries following balloon injury. Circ Res. 2008;103(4):378-87.
82. Wang L, et al. ADAMTS-7 mediates vascular smooth muscle cell migration and neointima formation in balloon-injured rat arteries. Circ Res. 2009;104(5):688-98.
83. Lee J, et al. MicroRNA-29b inhibits migration and proliferation of vascular smooth muscle cells in neointimal formation. J Cell Biochem. 2015;116(4):598-608.
84. Choe N, et al. The microRNA miR-34c inhibits vascular smooth muscle cell proliferation and neointimal hyperplasia by targeting stem cell factor. Cell Signal. 2015;27(6):1056-65.
85. Choe N, et al. The microRNA miR-132 targets Lrrfip1 to block vascular smooth muscle cell proliferation and neointimal hyperplasia. Atherosclerosis. 2013;229(2):348-55.
86. Klugherz BD, et al. Gene delivery from a DNA controlled-release stent in porcine coronary arteries. Nat Biotechnol. 2000;18(11):1181-4.
87. Thierry B, et al. Bioactive coatings of endovascular stents based on polyelectrolyte multilayers. Biomacromol. 2003;4(6):1564-71.
88. Jewell CM, et al. Release of plasmid DNA from intravascular stents coated with ultrathin multilayered polyelectrolyte films. Biomacromol. 2006;7(9):2483-91.
89. Hossfeld S, et al. Bioactive coronary stent coating based on layer-by-layer technology for siRNA release. Acta Biomater. 2013;9(5):6741-52.
90. Zhu X, Braatz RD. A mechanistic model for drug release in PLGA biodegradable stent coatings coupled with polymer degradation and erosion. J Biomed Mater Res A. 2015;103(7):2269-79.
91. Takahashi H, Letourneur D, Grainger DW. Delivery of large biopharmaceuticals from cardiovascular stents: a review. Biomacromol. 2007;8(11):3281-93.
92. Wang X, et al. Controlled release of sirolimus from a multilayered PLGA stent matrix. Biomaterials. 2006;27(32):5588-95.
93. Qiu XF, et al. Controlled release of siRNA nanoparticles loaded in a novel external stent prepared by emulsion electrospinning attenuates neointima hyperplasia in vein grafts. Zhonghua Yi Xue Za Zhi. 2009;89(41):2938-42.
94. Zhang L, et al. ADAMTS-7 promotes vascular smooth muscle cells proliferation in vitro and in vivo. Sci China Life Sci. 2015;58(7):674-81.
95. Sun J, et al. Preventing intimal thickening of vein grafts in vein artery bypass using STAT-3 siRNA. J Transl Med. 2012;10:2.
96. Banno H, et al. Controlled release of small interfering RNA targeting midkine attenuates intimal hyperplasia in vein grafts. J Vasc Surg. 2006;44(3):633-41.
97. Hartmann D, et al. MicroRNA-based therapy of Gata2-deficient vascular disease. Circulation. 2016;134:1973-90.
98. Lin J, et al. MicroRNA-181b inhibits thrombin-mediated endothelial activation and arterial thrombosis by targeting caspase recruitment domain family member 10. FASEB J. 2016;30(9):3216-26.
99. Qu Y, et al. VCAM-1 siRNA reduces neointimal formation after surgical mechanical injury of the rat carotid artery. J Vasc Surg. 2009;50(6):1452-8.
100. Chung J, et al. Discovery of novel peptides targeting pro-atherogenic endothelium in disturbed flow regions-targeted siRNA delivery to pro-atherogenic endothelium in vivo. Sci Rep. 2016;6:25636.
101. Leus NG, et al. VCAM-1 specific PEGylated SAINT-based lipoplexes deliver siRNA to activated endothelium in vivo but do not attenuate target gene expression. Int J Pharm. 2014;469(1):121-31.
102. Santel A, et al. A novel siRNA-lipoplex technology for RNA interference in the mouse vascular endothelium. Gene Ther. 2006;13(16):1222-34.
103. Walker T, et al. Inhibition of adhesion molecule expression on human venous endothelial cells by non-viral siRNA transfection. J Cell Mol Med. 2007;11(1):139-47.
104. Fehring V, et al. Delivery of therapeutic siRNA to the lung endothelium via novel lipoplex formulation DACC. Mol Ther. 2014;22(4):811-20.
105. Egorova A, et al. CXCR4-targeted modular peptide carriers for efficient anti-VEGF siRNA delivery. Int J Pharm. 2016;515(1-2):431-40.
106. Bhasin M, et al. Temporal network based analysis of cell specific vein graft transcriptome defines key pathways and hub genes in implantation injury. PLoS ONE. 2012;7(6):e39123.
107. Wang GJ, et al. Regulation of vein graft hyperplasia by survivin, an inhibitor of apoptosis protein. Arterioscler Thromb Vasc Biol. 2005;25(10):2081-7.
108. Hoel AW, et al. Regulation of vascular smooth muscle cell growth by survivin. Vascular. 2007;15(6):344-9.
109. Conte MS, Altieri DC. Survivin regulation of vascular injury. Trends Cardiovasc Med. 2006;16(4):114-7.
110. Simosa HF, et al. Survivin expression is up-regulated in vascular injury and identifies a distinct cellular phenotype. J Vasc Surg. 2005;41(4):682-90.
111. Herbert JM, et al. Protein kinase C alpha expression is required for heparin inhibition of rat smooth muscle cell proliferation in vitro and in vivo. J Biol Chem. 1996;271(42):25928-35.
112. Yu D, et al. MARCKS signaling differentially regulates vascular smooth muscle and endothelial cell proliferation through a KIS-, p27kip1- dependent mechanism. PLoS ONE. 2015;10(11):e0141397.
113. Yu D, et al. Myristoylated alanine-rich protein kinase substrate (MARCKS) regulates small GTPase Rac1 and Cdc42 activity and is a critical mediator of vascular smooth muscle cell migration in intimal hyperplasia formation. J Am Heart Assoc. 2015;4(10):e002255.
114. Monahan TS, et al. MARCKS silencing differentially affects human vascular smooth muscle and endothelial cell phenotypes to inhibit neointimal hyperplasia in saphenous vein. FASEB J. 2009;23(2):557-64.
115. Hao M, Li M, Li W. Galectin-3 inhibition ameliorates hypoxia-induced pulmonary artery hypertension. Mol Med Rep. 2017;15(1):160-8.
116. Elmen J, et al. Locked nucleic acid (LNA) mediated improvements in siRNA stability and functionality. Nucleic Acids Res. 2005;33(1):439-47.